TickerFacts.

Caris Life Sciences, Inc. (CAI): Revenue

Annual figures by period end, from SEC filings.

$812.03M
Year ended 2025-12-31
$989.61M
Trailing 12 months to 2026-06-30
2023-12-31: $306.13M2024-12-31: $412.26M2025-12-31: $812.03M$812.03M
2023-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$812.03M+97.0%2026-03-03, From 2025-01-01
2024-12-31$412.26M+34.7%2026-03-03, From 2024-01-01
2023-12-31$306.13Mn/a2026-03-03, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Caris Life Sciences, Inc. (CAI)2025-12-31$812.03M+97.0%
Guardant Health, Inc. (GH)2025-12-31$982.02M+32.9%
Veracyte, Inc. (VCYT)2025-12-31$517.14M+16.0%
CareDx, Inc. (CDNA)2025-12-31$379.81M+13.8%
Castle Biosciences Inc (CSTL)2025-12-31$344.23M+3.7%
RadNet, Inc. (RDNT)2025-12-31$2.04B+11.5%
Fulgent Genetics, Inc. (FLGT)2025-12-31$322.67M+13.8%
BillionToOne, Inc. (BLLN)2025-12-31$305.11M+100.0%
Natera, Inc. (NTRA)2025-12-31$2.31B+35.9%

Compare CAI, GH, VCYT, CDNA side by side · Screen every company in Services-Medical Laboratories ↗